US Doctors View DTC Ads For Prescription Drugs

26 August 1997

US doctors are responding cautiously to the high increase indirect-to-consumer advertising of prescription drugs. Mack Lipkin of New York University feels that while educating patients and getting them to ask questions have been proven to promote health, aggressive marketing campaigns could lead consumers to greatly misplaced enthusiasms.

Moreover, internist and cardiologist Thomas Lee told the New York Times that when patients come in asking if they should be on a particular medication, they are mildly suspicious that the doctor "has blown it" by not treating them with this. He commented that many of his colleagues feel that consumerism has gone too far and is a significant danger to the doctor-patient relationship. While patients have a right to know about these products, he said, doctors feel that pharmaceutical manufacturers are creating demand where often there is no real need.

One allergy specialist commented that his patients end up disappointed because the product they request turns out to be the same as the one they are already taking. However, a few doctors feel the advertisements provide an opening for a reasonable discussion, by alerting consumers that some symptoms can be treated. So far, the NYT reports, the trend toward asking for medicine has not moved into low-income patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight